ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag strategic immunology microbiology

Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
AIDS Research Progress Stymied By Narrow Focus, Critics Charge
Franklin Hoke | Jul 10, 1994 | 9 min read
Critics Charge Author: FRANKLIN HOKE, pp.1 Date: July 11,1994 Disputing what they see as unproductive preoccupation with HIV-specific studies, they step up campaign for a `wider window' of research Progress in AIDS research has faltered in the United States since the mid-1980s, according to some scientists, owing to a premature narrowing of the research focus by the scientific and administrative leadership of the National Inst
AIDS Research Progress Stymied By Narrow Focus, Critics Charge
Franklin Hoke | Jul 10, 1994 | 9 min read
Critics Charge Author: FRANKLIN HOKE, pp.1 Date: July 11,1994 Disputing what they see as unproductive preoccupation with HIV-specific studies, they step up campaign for a `wider window' of research Progress in AIDS research has faltered in the United States since the mid-1980s, according to some scientists, owing to a premature narrowing of the research focus by the scientific and administrative leadership of the National Inst
Human Clinical Trials Begin For Cervical Cancer Vaccines
Steve Bunk | Oct 26, 1997 | 6 min read
Efforts are under way to develop a vaccine against one of the world's deadliest illnesses, cervical cancer. Along with a number of university research laboratories, at least a half-dozen biotechnology and pharmaceutical companies are beginning clinical trials or are in preclinical development of such drugs. Efficacy in humans remains to be firmly established, but if the vaccines progress to later-phase trials, challenging jobs for immunologists, microbiologists, and biochemists will multiply. "

Run a Search

ADVERTISEMENT